Regenerex Pharma (RGPX) Change in Accured Expenses (2011 - 2025)

Regenerex Pharma (RGPX) has 13 years of Change in Accured Expenses data on file, last reported at $82384.0 in Q3 2025.

• Change in Accured Expenses for Q3 2025 came in at $82384.0, up 221.5% year-over-year; the trailing twelve-month figure through Sep 2025 was $64574.0 (down 71.02% YoY), and the FY2025 annual result was -$8983.0, down 103.09% from the prior year.
• Change in Accured Expenses improved to $82384.0 in Q3 2025 per RGPX's latest filing, from $20250.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $145699.0 in Q3 2023 and troughed at -$67808.0 in Q3 2024.
• A 5-year average of $27492.1 and a median of $16532.0 in 2021 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses sank 701.28% in 2023, then jumped 2186.69% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $11101.0 in 2021, then surged by 52.34% to $16911.0 in 2022, then surged by 472.91% to $96885.0 in 2023, then plunged by 83.95% to $15546.0 in 2024, then surged by 429.94% to $82384.0 in 2025.
• Business Quant data shows RGPX's Change in Accured Expenses at $82384.0 in Q3 2025, $20250.0 in Q2 2025, and -$53606.0 in Q1 2025.